The U.S. Food and Drug Administration (FDA) has granted approval to Roche’s New Drug Application (NDA) for Evrysdi (risdiplam), a tablet specifically designed for individuals living with spinal muscular atrophy (SMA). Evrysdi stands as the sole non-invasive treatment option that modifies the disease’s progression. The 5mg Evrysdi tablet can be swallowed whole or dispersed in water. “Evrysdi has robust potential to modify the SMA disease trajectory, and has already been used to treat tho...